CHICAGO—A new approach to dealing simultaneously with several of the identified molecular processes taking place in cancer has brought new prospects for extending life in patients with advanced non small-call lung cancer who have already received chemotherapy. The American Society of Clinical Oncology annual meeting heard phase II study findings from patients treated with ganetespib — a drug which inhibits heat shock protein, known as a “molecular chaperone” because it controls the activity of a number of different cancer-causing molecular processes. Used second line in combination with docetaxel the drug produced marked and highly significant improvements in progression-free and overall survival. Dr Suresh Ramalingam from Emory University in Atlanta discussed the study findings with Peter Goodwin.
You may also like...
Breast cancer: less radiotherapy in fewer hospital visits is just as good for preventing relapse 11 Dec, 2012 ASCO Annual Meeting Daily News Podcasts – June 4th, 2007 5 Jun, 2007 Audio Journal of Oncology Volume 16 Number 10 25 May, 2008 ASCO Audio Journal of Oncology in Advance – June 1st, 2007 – reporting from: American Association for Cancer Research Centennial Meeting, April 14-18, Los Angeles 2 Jun, 2007
- Previous story Cetuximab better than bevacizumab first-line in KRAS wild type expressing colorectal tumours
- Next story The WIN consortium meets in Paris – a boost for cancer science
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014